FDA’s Endocrinologic and Metabolic Drugs Advisory Committee backing for Janssen R&D LLC’s diabetes drug canagliflozin was tempered by recommendations from the Jan. 10 panel that its use be limited to patients with normal and mildly impaired renal function.
Canagliflozin Should Have Limitations Based On Renal Function, Panel Says
Several advisory committee members on both sides of a 10-5 vote voiced concern about using Janssen’s diabetes drug in patients with moderate renal impairment.